drugset / Trial / NCT01406704
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
RandomizedParallel-groupSingle-blindPrevention
Summary
This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).
Timeline
- Start
- 2004-01
- Primary completion
- 2010-12
- Completion
- 2013-12
Outcome
Outcome not reported
Stopped: “because of withdrawal of Avandia sale due to its risks outweigh its benefits”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosiglitazone | Small molecule | 8 mg | — |
| Subject | alpha-lipoic acid | Small molecule | 1800 mg | — |